Specific down regulation of 3T3-L1 adipocyte differentiation by cell-permeable antisense HIF1alpha-oligonucleotide.

Hypoxia is a strong modulator of angiogenesis, accelerating adipose tissue expansion, suggesting that hypoxia inducible factor 1alpha (HIF1alpha) can be a novel target for anti-obesity. We conjugated antisense-HIF1alpha-oligonucleotide (ASO) with low molecular weight protamine (LMWP), a cell-penetrating peptide, to enhance its ability to block hypoxic-angiogenesis, thereby eliciting an anti-obesity effect. Nano-sized ASO-LMWP (AS-L) conjugates enhanced cellular uptake of ASO without yielding a cytotoxic effect and protected the ASO against enzymatic attack and chemical reduction. AS-L showed enhanced intra-cellular localization compared to naked ASO and the complex of ASO with lipofectamine during hypoxic-differentiation. Consequently AS-L induced significant down-regulation of leptin and VEGF gene expressions, thereby reducing fat accumulation in the cell. This proof-of-concept study shows that AS-L produces an inhibitory effect on adipogenesis and angiogenesis during differentiation, indicating LMWP mediated ASO delivery can potentially be a safe and promising treatment for obesity.

[1]  M. Matsuda,et al.  Adipose Tissue Hypoxia in Obesity and Its Impact on Adipocytokine Dysregulation , 2007, Diabetes.

[2]  Wim E Hennink,et al.  Biodegradable polymers as non-viral carriers for plasmid DNA delivery. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[3]  C. Chung,et al.  Nontoxic membrane translocation peptide from protamine, low molecular weight protamine (LMWP), for enhanced intracellular protein delivery: in vitro and in vivo study , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[4]  B. Aguilera,et al.  Muscle binding peptides found by phage display as delivery agent for antisense oligonucleotides , 2008 .

[5]  A. Miller,et al.  Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection , 1990, Molecular and cellular biology.

[6]  P. Seth,et al.  Growth arrest and induction of apoptosis in breast cancer cells by antisense depletion of protein kinase A-RIα subunit: p53-independent mechanism of action , 1999, Molecular and Cellular Biochemistry.

[7]  D. Ingber,et al.  Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth , 1990, Nature.

[8]  G. Z. Rocha,et al.  Inhibition of hypothalamic Foxo1 expression reduced food intake in diet‐induced obesity rats , 2009, The Journal of physiology.

[9]  J. Lloyd,et al.  Relation between Age of Onset of Obesity and Size and Number of Adipose Cells , 1972, British medical journal.

[10]  R. Kole,et al.  Antisense Pharmacodynamics: Critical Issues in the Transport and Delivery of Antisense Oligonucleotides , 1999, Pharmaceutical Research.

[11]  K. Kataoka,et al.  Glutathione-sensitive stabilization of block copolymer micelles composed of antisense DNA and thiolated poly(ethylene glycol)-block-poly(L-lysine): a potential carrier for systemic delivery of antisense DNA. , 2001, Biomacromolecules.

[12]  M. Perricaudet,et al.  Adenovirus-mediated transfer of a recombinant alpha 1-antitrypsin gene to the lung epithelium in vivo. , 1991, Science.

[13]  V. Yang,et al.  Reduced reactivity towards anti-protamine antibodies of a low molecular weight protamine analogue. , 2001, Thrombosis research.

[14]  H. Soifer,et al.  Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents , 2009, Nucleic acids research.

[15]  Xiaolan Chen,et al.  Chemical modification of gene silencing oligonucleotides for drug discovery and development. , 2005, Drug discovery today.

[16]  O. Seksek,et al.  Delivery systems for antisense oligonucleotides. , 2000, Pharmacology & therapeutics.

[17]  Leaf Huang,et al.  Non-viral is superior to viral gene delivery. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[18]  S. Carotta,et al.  Different behavior of branched and linear polyethylenimine for gene delivery in vitro and in vivo , 2001, The journal of gene medicine.

[19]  B. Demeneix,et al.  Adenovirus enhancement of polyethylenimine-mediated transfer of regulated genes in differentiated cells , 1997, Gene Therapy.

[20]  H. Stunnenberg,et al.  Genome-wide profiling of PPARgamma:RXR and RNA polymerase II occupancy reveals temporal activation of distinct metabolic pathways and changes in RXR dimer composition during adipogenesis. , 2008, Genes & development.

[21]  H. Lijnen.  Angiogenesis and obesity. , 2008, Cardiovascular research.

[22]  D. Cunningham,et al.  Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  T. Wakefield,et al.  Low molecular weight protamine as nontoxic heparin/low molecular weight heparin antidote (III): Preliminary in vivo evaluation of efficacy and toxicity using a canine model , 2001, AAPS PharmSci.

[24]  R. Wagner.  Gene inhibition using antisense oligodeoxynucleotides , 1994, Nature.

[25]  Y. T. Ko,et al.  Liposome encapsulated polyethylenimine/ODN polyplexes for brain targeting. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[26]  N. Bottini,et al.  Conjugation of antisense oligonucleotides to PEGylated carbon nanotubes enables efficient knockdown of PTPN22 in T lymphocytes. , 2009, Bioconjugate chemistry.

[27]  V. Yang,et al.  Preliminary in vivo evaluation of the protein transduction domain-modified ATTEMPTS approach in enhancing asparaginase therapy. , 2009, Journal of biomedical materials research. Part A.

[28]  B. Cha,et al.  Assessment of the anti-obesity effects of the TNP-470 analog, CKD-732. , 2007, Journal of molecular endocrinology.

[29]  I. Castan-Laurell,et al.  Apelin/APJ signaling system: a potential link between adipose tissue and endothelial angiogenic processes , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[30]  I. S. Wood,et al.  Adipokines: inflammation and the pleiotropic role of white adipose tissue , 2004, British Journal of Nutrition.

[31]  G. Study.  Safety of intravitreous fomivirsen for treatment of cytomegalovirus retinitis in patients with AIDS , 2002 .

[32]  A. Dove.  Antisense and sensibility , 2002, Nature Biotechnology.

[33]  C. Vigouroux,et al.  Efficient adenoviral transduction of 3T3-F442A preadipocytes without affecting adipocyte differentiation. , 2005, Biochimie.

[34]  Rakesh K. Jain,et al.  Interstitial pH and pO2 gradients in solid tumors in vivo: High-resolution measurements reveal a lack of correlation , 1997, Nature Medicine.

[35]  R. L. Juliano,et al.  Conjugates of Antisense Oligonucleotides with the Tat and Antennapedia Cell-Penetrating Peptides: Effects on Cellular Uptake, Binding to Target Sequences, and Biologic Actions , 2004, Pharmaceutical Research.

[36]  Hagen von Briesen,et al.  Intracellular tracking of protamine/antisense oligonucleotide nanoparticles and their inhibitory effect on HIV-1 transactivation. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[37]  S. Sen,et al.  Polymersome delivery of siRNA and antisense oligonucleotides. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[38]  Bohan Wang,et al.  Hypoxia in adipose tissue: a basis for the dysregulation of tissue function in obesity? , 2008, British Journal of Nutrition.

[39]  K. Rice,et al.  Peptide-mediated gene delivery: influence of peptide structure on gene expression. , 1997, Bioconjugate chemistry.

[40]  Kinam Park.  Non-ionic polymersomes for delivery of oligonucleotides. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[41]  D. Sessler,et al.  Tissue Oxygenation in Obese and Non-obese Patients During Laparoscopy , 2005, Obesity surgery.

[42]  M. Hashida,et al.  Inhibition of peritoneal dissemination of tumor cells by single dosing of phosphodiester CpG oligonucleotide/cationic liposome complex. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[43]  Y. Yoshioka,et al.  Effective tumor targeted gene transfer using PEGylated adenovirus vector via systemic administration. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[44]  L. Philipson,et al.  HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[45]  G. Krissansen,et al.  Antisense hypoxia‐inducible factor 1α gene therapy enhances the therapeutic efficacy of doxorubicin to combat hepatocellular carcinoma , 2008, Cancer science.

[46]  A. Xu,et al.  Hypoxia dysregulates the production of adiponectin and plasminogen activator inhibitor-1 independent of reactive oxygen species in adipocytes. , 2006, Biochemical and biophysical research communications.

[47]  Y. Hao,et al.  RNAi-mediated gene silencing of vascular endothelial growth factor inhibits growth of colorectal cancer. , 2007, Cancer biotherapy & radiopharmaceuticals.

[48]  S. W. Kim,et al.  Low molecular weight protamine as an efficient and nontoxic gene carrier: in vitro study , 2003, The journal of gene medicine.

[49]  V. Yang,et al.  A Less Toxic Heparin Antagonist—Low Molecular Weight Protamine , 2004, Biochemistry (Moscow).

[50]  J. DeGregori,et al.  Construction of stable coxsackievirus and adenovirus receptor-expressing 3T3-L1 cells. , 2001, Journal of lipid research.

[51]  Alexandre A. Vetcher,et al.  Nonviral Nanoscale-Based Delivery of Antisense Oligonucleotides Targeted to Hypoxia-Inducible Factor 1α Enhances the Efficacy of Chemotherapy in Drug-Resistant Tumor , 2008, Clinical Cancer Research.

[52]  M. Hashida,et al.  Effect of DNA/liposome mixing ratio on the physicochemical characteristics, cellular uptake and intracellular trafficking of plasmid DNA/cationic liposome complexes and subsequent gene expression. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[53]  A. Zimmer,et al.  Antisense delivery using protamine-oligonucleotide particles. , 2000, Nucleic acids research.

[54]  B. Gazzard,et al.  Safety of intravitreous fomivirsen for treatment of cytomegalovirus retinitis in patients with AIDS. , 2002, American journal of ophthalmology.

[55]  S. Kawakami,et al.  Efficient peritoneal dissemination treatment obtained by an immunostimulatory phosphorothioate-type CpG DNA/cationic liposome complex in mice. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[56]  Xiubo Zhao,et al.  Controlled delivery of anti-sense oligodeoxynucleotide from multilayered biocompatible phosphorylcholine polymer films. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[57]  T. Greiner,et al.  Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  Junfeng Zhang,et al.  Targeting delivery oligonucleotide into macrophages by cationic polysaccharide from Bletilla striata successfully inhibited the expression of TNF-alpha. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[59]  J. Fleshman,et al.  Obesity Decreases Perioperative Tissue Oxygenation , 2004, Anesthesiology.

[60]  K. Braeckmans,et al.  Pegylation of liposomes favours the endosomal degradation of the delivered phosphodiester oligonucleotides. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[61]  M. Lafontan,et al.  Effects of hypoxia on the expression of proangiogenic factors in differentiated 3T3-F442A adipocytes , 2003, International Journal of Obesity.

[62]  M. Monsigny,et al.  Efficient gene transfer by histidylated polylysine/pDNA complexes. , 1999, Bioconjugate chemistry.

[63]  C. M. Roth,et al.  Novel graft copolymers enhance in vitro delivery of antisense oligonucleotides in the presence of serum. , 2009, Journal of controlled release : official journal of the Controlled Release Society.